Genetic causal attribution of epilepsy and its implications for felt stigma.

Sabatello M, Phelan JC, Hesdorffer DC, Shostak S, Goldsmith J, Sorge ST, et al. Genetic causal attribution of epilepsy and its implications for felt stigma. Epilepsia. 2015;56(10):1542-50. DOI: 10.1111/epi.13113. PubMed PMID: 26290354.

The other side of epilepsy.

Tuchman R, Loring DW. The other side of epilepsy. Epilepsia. 2015;56(10):1490-1. DOI: 10.1111/epi.13104. PubMed PMID: 26293340.

Epileptic activity is a surrogate for an underlying etiology and stopping the activity has a limited impact on developmental outcome.

Korff CM, Brunklaus A, Zuberi SM. Epileptic activity is a surrogate for an underlying etiology and stopping the activity has a limited impact on developmental outcome. Epilepsia. 2015;56(10):1477-81. DOI: 10.1111/epi.13105. PubMed PMID: 26293471.

Epileptic encephalopathies: Optimizing seizure control and developmental outcome.

Jehi L, Wyllie E, Devinsky O. Epileptic encephalopathies: Optimizing seizure control and developmental outcome. Epilepsia. 2015;56(10):1486-9. DOI: 10.1111/epi.13107. PubMed PMID: 26293588.

Should epileptiform discharges be treated?

Fernández IS, Loddenkemper T, Galanopoulou AS, Moshé SL. Should epileptiform discharges be treated?. Epilepsia. 2015;56(10):1492-504. DOI: 10.1111/epi.13108. PubMed PMID: 26293670.

Seizing control of epileptic activity can improve outcome.

Chapman KE, Specchio N, Shinnar S, Holmes GL. Seizing control of epileptic activity can improve outcome. Epilepsia. 2015;56(10):1482-5. DOI: 10.1111/epi.13109. PubMed PMID: 26293783.

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91(3):483-8. DOI: 10.1038/clpt.2011.251. PubMed PMID: 22278332; PubMed Central PMCID: PMC4038037.

The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia.

Gullo D, Gelsomino R, Marturano I, Restivo D, Arpi ML, Leonardi D, et al. The antiepileptic drug carbamazepine can cause adrenal insufficiency in patients under hormone replacement therapy for congenital adrenal hyperplasia. Hormones (athens). 2013;12(3):470-1. PubMed PMID: 24121390.

Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52(12):1045-61. DOI: 10.1007/s40262-013-0088-z. PubMed PMID: 23794036.

The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population.

Moon J, Park H-K, Chu K, Sunwoo J-S, Byun J-I, Lim J-A, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population. Epilepsia. 2015;56(10):e161-7. DOI: 10.1111/epi.13087. PubMed PMID: 26282450.